Research Study

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF)
Principal Investigator 
Jason Andrade

Overview

Body Locations and Systems 
Atrial Fibrillation
Disorders and Conditions 
Mild Cognitive Impairment
ClinicalTrials.gov# 
NCT02387229
Status 
Recruiting
Study Start/End 
Aug 26, 2015 to Dec 31, 2021
Locations 
Vancouver General Hospital
Name/Title 
Falisha Adatia, Research Coordinator
Phone 
604-875-4065
Email Address 
falisha.adatia@vch.ca
Purpose of Study 

This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to acetylsalicylic acid in reducing stroke, transient ischemic attack (TIA) and neurocognitive decline, in subjects with non-valvular AF and with low risk of stroke.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.